LATEST PRESS RELEASES

183 views4 min read

Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive shares in Lobe ... Read More...
32 views5 min read

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Jan. 19, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has submitted the updated briefing package to the U.S. Food &... Read More...
32 views8 min read

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin
- Study supports earlier findings and demonstrates that Kernel Flow provides a functional measure of blood oxygenation changes in the brain associated with neural activity -TORONTO, January 18, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psyc... Read More...
M & A47 views8 min read

Red Light Holland Furthers Collaboration With CCrest Laboratories to Develop Homogenized Microdosing Capsules Aimed At Emerging Legal Markets, Utilizing A Fourth Health Canada Approved Psilocybin Import Permit and New Authorization for Assembly

Red Light Holland
Red Light Holland to export another 3000 Grams (3KG) of Psilocybin Truffles, produced and sold in The Netherlands, into Canada under a fourth Health Canada approved psilocybin import permit to its laboratory partner, CCrest Laboratories Inc., a cGMP pharmaceutical laboratory in Montreal, CanadaCCrest Labs to utilize its newly amended Cont... Read More...
1276 views6 min read

Dried Mushroom Market to Reach $8.6 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research

Allied
Multiple nutritional benefits of consuming dried mushrooms are raising the demand for it, which in turn, is driving the growth of the global dried mushroom market. PORTLAND, Ore., Jan. 13, 2023 -- Allied Market Research published a report, titled, "Dried Mushroom Market by Type (Button, Shiitake, Oyster, Other), by Application (Food Servi... Read More...
46 views4 min read

Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Jan. 12, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an updated briefing package to the U.S. Food & Drug Administr... Read More...
1064 views4 min read

Revive Therapeutics Ltd. Closes $4.3 Million Offering

Revive Therapeutics
TORONTO, Jan. 12, 2023 -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF; FRANKFURT:31R) (“Revive” or the “Company”) is pleased to announce that it has completed the closing of its previously announced private placement (the “Offering”) by issuing a total of 28,676,064 units (each, a “Unit”), at a price of $0.15 per Unit, for gross proc... Read More...
443 views9 min read

Red Light Holland Engages CLE, Licensing Experts, to Assist with Obtaining Controlled Drugs and Substances Dealer’s Licence

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - January 11, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psiloc... Read More...
M & A602 views12 min read

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

Psyence Group
VANCOUVER, British Columbia, Jan. 09, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) formed for the purpose of acquir... Read More...
825 views4 min read

Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants

Revive Therapeutics
TORONTO, Jan. 09, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to R... Read More...
65 views3 min read

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Jan. 05, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Comp... Read More...
47 views3 min read

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Dec. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has submitted the Type C meeting request package to the U.S. Food & ... Read More...
1181 views8 min read

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Psyence Group
VANCOUVER, British Columbia, Dec. 15, 2022 -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life science biotechnology company pioneering the use ... Read More...
620 views5 min read

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group
Psyence Group Inc.TORONTO, Dec. 14, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement o... Read More...
53 views11 min read

Red Light Holland Announces Happy Caps Mushroom Home Grow Kits Are Now Available in 13 Loblaws’ Real Canadian Superstores across Ontario, Exceeding 70 Retail Stores Across Canada

Red Light Holland
Loblaws has accepted Happy Caps Home Grow Kits in 13 of their Real Canadian Superstores, with a plan to add additional locations in calendar Q1 2023 With the addition of Loblaws, Happy Caps Grow Kits are now available in over 70 retail stores in Canada, including 3 Canadian Tire storesHappy Caps sold 7,816 units from Nov 21, 2022 - Dec 11... Read More...
770 views5 min read

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Mydecine Innovations Group
DENVER, Dec. 12, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated Septemb... Read More...
672 views4 min read

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

Numinus Wellness
New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety. VANCOUVER, BC, Dec. 8, 2022 - Numinus Wellness ... Read More...
Capital Raise534 views4 min read

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce tha... Read More...
331 views4 min read

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

BetterLife Pharma
VANCOUVER, British Columbia, Dec. 02, 2022 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that one of its scientific collaborators, Dr. Argel Aguil... Read More...
991 views4 min read

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its p... Read More...
1107 views7 min read

GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

Psyence Group
TORONTO, Nov. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), ente... Read More...
Financials1036 views4 min read

Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call

Field Trip Health
TORONTO, Nov. 28, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" of “Field Trip”), a global leader in the delivery of psychedelic therapies, announced today that it now plans to release financial results for its fiscal 2023 second quarter for the three-month period ended September 30, 2022, after market close on... Read More...
Capital Raise362 views4 min read

Bright Minds Biosciences Announces Non-Brokered Private Placement

Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a n... Read More...
125 views3 min read

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Nov. 24, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food &a... Read More...
67 views4 min read

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Nov. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a ... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!